Wound Management News

ORLANDO — Innovations in treating burn and trauma scars in recent years include updated laser technology, giving practitioners options to help in these difficult cases, according to a speaker here.

The European Medicines Agency’s Committee for Medicinal Products for Human Use recommended the approval of Vyjuvek for the treatment of wounds in patients with dystrophic epidermolysis bullosa, Krystal Biotech announced in a press release.

 The supplemental biologics license application for Dupixent for the treatment of bullous pemphigoid in adults has been accepted by the FDA for priority review, Sanofi announced in a press release.

Researchers found a direct relationship between cutaneous chronic graft-versus-host disease and health-related quality-of-life domains that are not currently included as measurements in clinical trials, according to a study.

An in-depth interview about the effects of the CMS’s 2025 physician fee schedule on patient access topped Healio Dermatology’s most-read articles of November, with FDA news also garnering attention.

DALLAS — In this video from the American Association of Hip and Knee Surgeons Annual Meeting, Robert A. Burnett, MD, discussed results that showed repeat mesh glue dressing exposure yielded a fivefold increased risk of allergic dermatitis.

The CMS finalized cuts to the 2025 physician fee schedule for the fifth year in a row, prompting an urgent call-to-action from the American Academy of Dermatology. HHS, through the CMS, announced the finalization of the 2025 Medicare Physician Fee Schedule.

The FDA has issued a 510(k) clearance to Imbed Biosciences to market Microlyte Ag/Lidocaine for the management of painful skin wounds, the company announced in a press release.

The FDA granted rare pediatric disease designation for BPM31510T for the treatment of epidermolysis bullosa, BPGbio announced in a press release.